ono-11113
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT01484912)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Prostanoid FP receptorAGONIST
PTGFR agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 5-heptenoic acid, 7-(3-(3-hydroxy-1-octenyl)-6-thiabicyclo(3.1.1)hept-2-yl)-, (1alpha,2beta(z),3alpha(1e,3r*),5alpha)-
- 9,11-epithio-11,12-methanothromboxane a2
- 9,11-epithio-11,12-methano-txa2
- ono 11113
- ono-11113
- sta2
- sta 2
- sta-2
- sta-2
- sta-2
- stxa2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01484912 | Phase 2 | May 1, 2007 | National Taiwan University, Sinphar Pharmaceutical Co., Ltd |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Taiwan University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Sinphar Pharmaceutical Co., Ltd | For profit | 1 | 1 | 1 | 2007 |
2 organizations
Page 1 / 1